YHYuan‐Shung Huang

Yuan‐Shung Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuan‐Shung Huang has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort

    by Daniel J Zheng, Gary Hettinger, Catherine Aftandilian, Kira Bona, Emi H Caywood, Anderson B Collier, Caitlin W Elgarten, Cody Gathers, Taumoha Ghosh, M Monica Gramatges, et al.

    Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children’s Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.


  • Open Access

    Alterations in Liver Perfusion in Adults With Fontan Circulation as Assessed by Dual Cholate Clearance

    by Yuli Y. Kim, Annique Nyman, Yuan‐Shung Huang, Alexis Z. Tomlinson, Michael P. McRae, Greg T. Everson, Sumeet Vaikunth, Benjamin Rosenthal, Jack Rychik, Maarouf A. Hoteit

    Background: Fontan circulation (FC) in complex congenital heart disease is characterized by altered hemodynamics and associated with Fontan‐associated liver disease. Patients with FC may exhibit abnormalities in cholate clearance due to abnormal perfusion. We aimed to compare cholate clearance in adults with FC to healthy controls and explore associations between cholate clearance and clinical features. Methods and Results: This is a prospective cohort study of patients with FC ≥18 years of age between 2019 and 2022. Systemic and portal hepatic clearance of cholate was assessed using a dual cholate clearance assay (HepQuant Shunt), measuring systemic and portal hepatic filtration rates (HFRs). Systemic HFR/portal HFR ratio (SHUNT%) was calculated. Participants with FC and healthy controls were compared using the Fisher exact test and Wilcoxon test. Univariable regression and multivariable analyses determined associations with clinical variables. There were 35 participants with FC (54% women; median age 29.0 years [interquartile range, 24.0–36.0], 91% White) and 26 controls. In addition to lower platelet counts and higher aspartate aminotransferase to platelet ratio index, and Fibrosis‐4 indices, FC participants had lower systemic HFR and portal HFR. SHUNT% was comparable with controls but ranged from 8% to 76%, with 8 (23%) having SHUNT% >30%. In those with FC, increase in SHUNT% was associated with elevated Fontan pressure, higher aortopulmonary collateral flow, decreased oxygen saturation, elevated NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels, thrombocytopenia, and Fibrosis‐4 ≥1.45. Conclusions: Cholate clearance, as defined by systemic and portal HFR, is impaired in those with FC. Features of worse Fontan physiology correlate with higher SHUNT%, supporting the hypothesis that hemodynamic derangements play a role in progression of Fontan‐associated liver disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03726229.


  • Open Access

    Importance of risk adjusting central line-associated bloodstream infection rates in children

    by Lakshmi Srinivasan, Ashley Oliver, Yuan-Shung V Huang, Di Shu, Kait M Donnelly, Cecelia Harrison, Amy L. Roberts, Ron Keren

    Objective: Central line-associated bloodstream infection (CLABSI) is one of the most prevalent pediatric healthcare-associated infections and is used to benchmark hospital performance. Pediatric patients have increased in acuity and complexity over time. Existing approaches to risk adjustment do not control for individual patient characteristics, which are strong predictors of CLABSI risk and vary over time. Our objective was to develop a risk adjustment model for CLABSI in hospitalized children and compare observed to expected rates over time.Design and Setting: We conducted a prospective cohort study using electronic health record data at a quaternary Children’s Hospital.Patients: We included hospitalized children with central catheters.Methods: Risk factors identified from published literature were considered for inclusion in multivariable modeling based on association with CLABSI risk in bivariable analysis and expert input. We calculated observed and expected (risk model-adjusted) annual CLABSI rates.Results: Among 16,411 patients with 520,209 line days, 633 patients experienced 796 CLABSIs. The final model included age, behavioral health condition, non-English speaking, oncology service, port catheter type, catheter dwell time, lymphatic condition, total parenteral nutrition, and number of organ systems requiring ICU level care. For every organ system receiving ICU level care the odds ratio for CLABSI was 1.24 (95% CI 1.12–1.37). Although not statistically different, observed rates were lower than expected rates for later years.Conclusions: Failure to adjust for patient factors, particularly acuity and complexity of disease, may miss clinically significant differences in CLABSI rates, and may lead to inaccurate interpretation of the impact of quality improvement efforts.


  • Prolonged Inotrope Use After Surgery for Congenital Heart Disease: A Common Occurrence with a High Burden of Mortality

    by Alicia M. Kamsheh, Warren B. Bilker, Yuan-Shung Huang, Oluwatimilehin Okunowo, Danielle S. Burstein, Jonathan B. Edelson, Kimberly Y. Lin, Katsuhide Maeda, Constantine D. Mavroudis, Matthew J. O’cOnnor, et al.

    Outcomes in patients requiring prolonged inotropes (PI) following surgery for congenital heart disease (CHD) have not been well studied. We aimed to describe the burden of PI use in the immediate postoperative period after CHD surgery and identify risk factors for in-hospital mortality. We conducted a retrospective cohort study using the Pediatric Health Information System® (PHIS) database. Patients 0–18 years with CHD who underwent cardiovascular surgery from 2010 to 2020 were included. Patients who received inotropic medications for > 7 consecutive days after surgery were in the PI group and all others in the control group. Patients who died before 7 days were excluded. Multivariable mixed-effect logistic regression was used to examine risk factors for in-hospital mortality. There were 110,271 patients from 48 centers included, 10,292 in the PI group and 99,979 in the control group. In-hospital mortality was significantly higher in the PI group (24.9% vs. 4.6%, p < 0.001). Ventricular assist device use was rare (1.6%). After adjustment, odds of in-hospital mortality in the PI group was 3.5 (95% CI 3.3–3.8) times higher than in controls. Independent risk factors for in-hospital mortality were age, non-White race, class of CHD, number of complex chronic conditions, preoperative inotrope, preoperative extracorporeal membrane oxygenation, sepsis, stroke, renal failure, number of inotropes at 7 days, and discharge year (p < 0.01 for all). Postoperative PI use in CHD is common and carries a considerable burden of mortality. Additional work is needed to understand which risk factors are modifiable and which patients may benefit from reintervention or advanced heart failure therapies.


  • Open Access

    Healthcare utilization disparities among children with high‐risk neuroblastoma treated on Children's Oncology Group clinical trials

    by Jamie Shoag, Yimei Li, Kelly D. Getz, Yuan‐Shung Huang, Matt Hall, Arlene Naranjo, Troy Richardson, Ami V. Desai, Puja J. Umaretiya, Rahela Aziz‐Bose, et al.

    Introduction: Disparities in relapse and survival from high‐risk neuroblastoma (HRNBL) persist among children from historically marginalized groups even in highly standardized clinical trial settings. Research in other cancers has identified differential treatment toxicity as one potential underlying mechanism. Whether racial and ethnic disparities in treatment‐associated toxicity exist in HRNBL is poorly understood.Methods: This is a retrospective study utilizing a previously assembled merged cohort of children with HRNBL on Children's Oncology Group (COG) post‐consolidation immunotherapy trials ANBL0032 and ANBL0931 at Pediatric Health Information System (PHIS) centers from 2005 to 2014. Race and ethnicity were categorized to reflect historically marginalized populations as Hispanic, non‐Hispanic Black (NHB), non‐Hispanic other (NHO), and non‐Hispanic White (NHW). Associations between race‐ethnicity and intensive care unit (ICU)‐level care utilization as a proxy for treatment‐associated toxicity were examined with log binomial regression and summarized as risk ratio (RR) and corresponding 95% confidence interval (CI).Results: The analytic cohort included 370 children. Overall, 88 (23.8%) patients required ICU‐level care for a median of 3.0 days (interquartile range [IQR]: 1.0–6.5 days). Hispanic children had nearly three times the risk of ICU‐level care (RR 3.1, 95% CI: 2.1–4.5; fully adjusted RR [aRR] 2.5, 95% CI: 1.6–3.7) compared to NHW children and the highest percentage of children requiring cardiovascular‐driven ICU‐level care.Conclusion: Children of Hispanic ethnicity with HRNBL receiving clinical trial‐delivered therapy were more likely to experience ICU‐level care compared to NHW children. These data suggest that further investigation of treatment‐related toxicity as a modifiable mechanism underlying outcome disparities is warranted.


  • Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data

    by Lusha Cao, Yuan‐Shung Huang, Kelly D. Getz, Alix E. Seif, Jenny Ruiz, Tamara P. Miller, Brian T. Fisher, Richard Aplenc, Yimei Li

    Case identification in administrative databases is challenging as diagnosis codes alone are not adequate for case ascertainment. We utilized machine learning (ML) to efficiently identify pediatric patients with newly diagnosed acute lymphoblastic leukemia. We tested nine ML models and validated the best model internally and externally. The optimal model had 97% positive predictive value (PPV) and 99% sensitivity in internal validation; 94% PPV and 82% sensitivity in external validation. Our ML model identified a large cohort of 21,044 patients, demonstrating an efficient approach for cohort assembly and enhancing the usability of administrative data.


  • Open Access

    The effectiveness and safety of antibody induction immunosuppression in a large cohort of United States pediatric liver transplant recipients

    by Phoebe Wood, Yuan-Shung Huang, Lucia Sanchez, Eimear Kitt, Peter L. Abt, Therese Bittermann


  • Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database

    by Lusha Cao, Yuan‐Shung Huang, Chao Wu, Kelly Getz, Tamara P. Miller, Jenny Ruiz, Brian T. Fisher, Alix E. Seif, Richard Aplenc, Yimei Li

    Background: Administrative datasets are useful for identifying rare disease cohorts such as pediatric acute myeloid leukemia (AML). Previously, cohorts were assembled using labor‐intensive, manual reviews of patients’ longitudinal chemotherapy data.Methods: We utilized a two‐step machine learning (ML) method to (i) identify pediatric patients with newly diagnosed AML, and (ii) among the identified AML patients, their chemotherapy courses, in an administrative/billing database. Using 2558 patients previously manually reviewed, multiple ML algorithms were derived from 75% of the study sample, and the selected model was tested in the remaining hold‐out sample. The selected model was also applied to assemble a new pediatric AML cohort and further assessed in an external validation, using a standalone cohort established by manual chart abstraction.Results: For patient identification, the selected Support Vector Machine model yielded a sensitivity of 0.97 and a positive predictive value (PPV) of 0.97 in the hold‐out test sample. For course‐specific chemotherapy regimen and start date identification, the selected Random Forest model yielded overall PPV greater than or equal to 0.88 and sensitivity greater than or equal to 0.86 across all courses in the test sample. When applied to new cohort assembly, ML identified 3016 AML patients with 10,588 treatment courses. In the external validation subset, PPV was greater than or equal to 0.75 and sensitivity was greater than or equal to 0.82 for patient identification, and PPV was greater than or equal to 0.93 and sensitivity was greater than or equal to 0.94 for regimen identifications.Conclusion: A carefully designed ML model can accurately identify pediatric AML patients and their chemotherapy courses from administrative databases. This approach may be generalizable to other diseases and databases.


  • Open Access

    Center Variability in Acute Rejection and Biliary Complications After Pediatric Liver Transplantation

    by Mounika Kanneganti, Yuwen Xu, Yuan‐Shung Huang, Eimear Kitt, Brian T. Fisher, Peter L. Abt, Elizabeth B. Rand, Douglas E. Schaubel, Therese Bittermann

    Transplant center performance and practice variation for pediatric post–liver transplantation (LT) outcomes other than survival are understudied. This was a retrospective cohort study of pediatric LT recipients who received transplants between January 1, 2006, and May 31, 2017, using United Network for Organ Sharing (UNOS) data that were merged with the Pediatric Health Information System database. Center effects for the acute rejection rate at 1 year after LT (AR1) using UNOS coding and the biliary complication rate at 1 year after LT (BC1) using inpatient billing claims data were estimated by center‐specific rescaled odds ratios that accounted for potential differences in recipient and donor characteristics. There were 2216 pediatric LT recipients at 24 freestanding children’s hospitals in the United States during the study period. The median unadjusted center rate of AR1 was 36.92% (interquartile range [IQR], 22.36%‐44.52%), whereas that of BC1 was 32.29% (IQR, 26.14%‐40.44%). Accounting for recipient case mix and donor factors, 5/24 centers performed better than expected with regard to AR1, whereas 3/24 centers performed worse than expected. There was less heterogeneity across the center effects for BC1 than for AR1. There was no relationship observed between the center effects for AR1 or BC1 and center volume. Beyond recipient and allograft factors, differences in transplant center management are an important driver of center AR1 performance, and less so of BC1 performance. Further research is needed to identify the sources of variability so as to implement the most effective solutions to broadly enhance outcomes for pediatric LT recipients.


  • Open Access

    Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma

    by Kira Bona, Yimei Li, Lena E Winestone, Kelly D Getz, Yuan-Shung Huang, Brian T Fisher, Ami V Desai, Troy Richardson, Matt Hall, Arlene Naranjo, et al.

    Whether social determinants of health are associated with survival in the context of pediatric oncology–targeted immunotherapy trials is not known. We examined the association between poverty and event-free survival (EFS) and overall survival (OS) for children with high-risk neuroblastoma treated in targeted immunotherapy trials. We conducted a retrospective cohort study of 371 children with high-risk neuroblastoma treated with GD2-targeted immunotherapy in the Children’s Oncology Group trial ANBL0032 or ANBL0931 at a Pediatric Health Information System center from 2005 to 2014. Neighborhood poverty exposure was characterized a priori as living in a zip code with a median household income within the lowest quartile for the cohort. Household poverty exposure was characterized a priori as sole coverage by public insurance. Post hoc analyses examined the joint effect of neighborhood and household poverty using a common reference. All statistical tests were 2-sided. In multivariable Cox regressions adjusted for disease and treatment factors, household poverty–exposed children experienced statistically significantly inferior EFS (hazard ratio [HR] = 1.90, 95% confidence interval [CI] = 1.28 to 2.82, P = .001) and OS (HR = 2.79, 95% CI = 1.63 to 4.79, P < .001) compared with unexposed children. Neighborhood poverty was not independently associated with EFS or OS. In post hoc analyses exploring the joint effect of neighborhood and household poverty, children with dual-poverty exposure (neighborhood poverty and household poverty) experienced statistically significantly inferior EFS (HR = 2.21, 95% CI = 1.48 to 3.30, P < .001) and OS (HR = 3.70, 95% CI = 2.08 to 6.59, P < .001) compared with the unexposed group. Poverty is independently associated with increased risk of relapse and death among neuroblastoma patients treated with targeted immunotherapy. Incorporation of social and environmental factors in future trials as health-care delivery intervention targets may increase the benefit of targeted therapies.